干擾素-γ(IFN-γ)通過與單個(gè)高親和力受體IFN-γ受體相互作用而發(fā)揮其生物學(xué)效應(yīng)。這種受體存在于除成熟紅細(xì)胞外的幾乎所有細(xì)胞類型上。IFN-γ受體由兩條多肽鏈α和β組成,并且需要JAK 1、JAK 2和Stat 1的締合用于IFN-γ信號(hào)轉(zhuǎn)導(dǎo)。在信號(hào)轉(zhuǎn)導(dǎo)中,IFN-γ誘導(dǎo)IFN-γ受體α(IFNGR 1)的酪氨酸磷酸化,導(dǎo)致在活化受體上形成Stat 1的對(duì)接位點(diǎn),其特異性地活化IFN-γ誘導(dǎo)的基因轉(zhuǎn)錄。IFN-γ受體在結(jié)構(gòu)上與最近克隆的IL-10受體相關(guān)。GIR 208結(jié)合IFNGR 1并阻斷IFN-γ與受體的結(jié)合。 原液抗人PD-L2(3.2)抗體該產(chǎn)品同種型對(duì)照:Mouse IgG1 Isotype Control for In Vivo - Low Endotoxin [HKSP] (ICH2247) 緩沖液:ICH3001-100ml,nICH3002-100ml,nICH3003-100ml, 濃度:1.0 - 5.0 mg/ml 純度:>95% by SDS-PAGE and HPLC 內(nèi)毒素:≤ 1.0 EU/mg as determined by the LAL method 制劑:No carrier proteins or preservatives added in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl.